BioNTech (BNTX) says 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies

BioNTech's outlook for 2026 highlights a significant pipeline of oncology milestones and clinical trials, which positions the company for potential growth and increased market presence.

Newsquawk StaffPublished 12 Jan 2026, 12:06 UTCOn the live feed at 11:46 UTC — 3 more headlines followed before this page went public

Newsquawk headlinesUTC

12:00

Moderna (MRNA) 2025 revenue outlook of about USD 1.9bln (exp. USD 1.89bln) and improving 2025 expected GAAP operating expenses by USD 200mln to USD 5-5.2bln

11:49

EU Commission Spokesperson says that they stand ready to propose new and more severe sanctions on Iran

11:46

BioNTech (BNTX) says 2026 poised to be a catalyst-rich year for BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapies

11:34

EU Commission Spokesperson says the Mercosur deal can be applied without being ratified by the European Parliament

11:31

Lululemon (LULU) expects Q4 2025 net revenue and diluted EPS at the upper end of a USD 3.500-3.585bln and USD 4.66-4.76 range

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Try the platform free

Free. No signup, no card.

Expected 2026 oncology milestones include seven late-stage data readouts and to have 15 Phase 3 clinical trials ongoing by year end
Additional late-stage trial readouts through 2030+ set to create multiple launch opportunities across tumour types, building BioNTech into a multi-product oncology company
Financial strength with EUR 17.2 billion in cash and cash equivalents plus security investments, COVID-19 vaccine revenue stream, disciplined R&D spend, and strategic partnerships will continue to enable sustainable innovation.

Context

This emphasis on a diverse range of late-stage trials suggests that investors may view BioNTech as evolving into a multi-product oncology player, supported by its strong financials. Overall, this could lead to positive sentiment in the biotech sector, particularly among investors focused on innovative therapeutics.

All markets · last 90 days

Recent headlines that moved markets

FX/9 Sept · 15:01 UTC

US Treasury Buyback: Treasury to buy back a maximum of USD 6bln in 10-20year Treasuries on Thursday (vs guidance for at least USD 4bln).

USD/JPY, after we published+0.4%

USD/JPY rose over 50 pips as DXY strengthened.

ENERGY/8 Sept · 19:50 UTC

Iran launched an attack against US Navy ships on Monday that the US military has yet to acknowledge, WSJ reports, citing US officials.

Brent crude, after we published+0.8%

EQUITIES/8 Sept · 05:24 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Equity indices, after we published−0.3%

ENERGY/8 Sept · 05:23 UTC

Saudi Energy Minister says a number of energy facilities and utilities were hit; are temporarily halting some operations.

Brent Nov'26, after we published+1.0%

ENERGY/3 Sept · 08:03 UTC

Russian President Putin says that Russia and Ukraine should agree first; he notes that there is an opportunity to reach a peace agreement.

with Brent Nov, after we published−1.3%

EQUITIES/3 Sept · 04:54 UTC

North Korea stripped references to "peaceful unification" with South Korea from the charter of its ruling Workers' Party of Korea, according to Yonhap.

Equity indices, after we published−3.3%

Newsquawk Daily

Get both market opens in your inbox.

This note and the other one — the EU open and the US open, every business day, written by the desk. No account needed.

Related headlines

The whole workspace, free to try.

© 2026 Newsquawk. All rights reserved.